DBV Technologies Board Member Resignation Announced
DBV Technologies, a prominent clinical-stage biopharmaceutical company residing in the realm of immunologic treatment development, has made a significant announcement regarding its Board of Directors. Executives and shareholders alike were informed about the immediate resignation of Daniel Soland. His journey with DBV began in 2015, and over the years, his contributions have made a lasting impact on the company.
A Commitment to Excellence
In expressing gratitude, Michel de Rosen, the Chairman of the Board, stated, "On behalf of the Board, DBV’s management team, and shareholders, I thank Daniel for his commitment to the Company." Such words reflect the valued insights and expertise Soland brought to discussions, especially during his tenure with the Compensation Committee. His departure is seen not only as a loss for the board but also as a moment to reflect on the journey taken together over the last decade.
In response, Soland commented, "It has been a pleasure to serve on the Board and work with the DBV management team." His personal investment in the company's vision remains strong, as he looks forward to seeing the progression of the VIASKIN® Peanut patch, which operates pioneering immunotherapy solutions aimed at benefiting children suffering from peanut allergies.
Continuing with an Informed Board
Despite this shake-up, the Board of Directors will now continue its operations with nine members as they prepare to conduct an assessment through the Nomination and Governance Committee. The upcoming discussions will revolve around finding a suitable individual to take on Soland’s role, with considerations slated for ratification during the next Annual General Meeting. This structured approach will ensure that DBV remains stable and efficient during this transitional period, aligning with its broader goals.
DBV Technologies' Mission and Vision
DBV Technologies holds a central mission: to develop innovative treatments for food allergies and other immunologic conditions that are desperately needed in the medical community. Focusing on the proprietary VIASKIN® patch technology, they target a range of allergic issues contributing to severe health reactions, from mild discomfort to life-threatening situations.
This groundbreaking technology offers a unique delivery system through epicutaneous immunotherapy (EPIT), designed to retrain the immune system. Millions of individuals—particularly children—are affected by food allergies, creating a significant demand for effective treatment methods. As DBV Technologies progresses with clinical trials involving peanut allergic toddlers and children, the results could bring hope and relief to many families facing allergic challenges.
Looking Ahead for DBV
With headquarters located in Châtillon, France, and North American operations in Warren, NJ, DBV Technologies continues to expand its footprint in the biopharmaceutical landscape. Their shares are actively traded on Euronext Paris as well as the Nasdaq Capital Market, under the ticker symbols DBV and DBVT respectively, allowing a wider audience to invest in their evolving story.
Commitment to Stakeholders
The company stands firm in its dedication to transform the care of food-allergic patients, investing in research and pioneering methodologies that will empower families managing these challenging health conditions. Their ongoing commitment to innovation aims to reshape the allergic landscape as we know it.
As they navigate through this transitional phase with a solidified focus on their strategic objectives, the team at DBV Technologies remains optimistic about their future endeavors.
Frequently Asked Questions
What led to Daniel Soland's resignation?
Daniel Soland resigned from the Board to pursue other opportunities, reflecting on his significant contributions over the years.
How does DBV Technologies plan to fill the vacancy left by Soland?
The Nomination and Governance Committee will evaluate candidates for the position, with a new member to be appointed pending shareholder approval.
What is the focus of DBV Technologies?
The company is dedicated to developing innovative treatment options for food allergies and other serious immunologic conditions.
How does the VIASKIN® patch technology work?
It uses epicutaneous immunotherapy (EPIT) to retrain the immune system by delivering microgram amounts of allergens through the skin, helping patients become less sensitive.
Where is DBV Technologies headquartered?
The company is headquartered in Châtillon, France, with operational arms in North America based in Warren, New Jersey.
